HOVON503/EMN24

HOVON503/EMN24

Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL) 


Study treatments


Inclusion criteria

Exclusion criteria

Participating sites


Link